FDA Approves Shockwave Coronary Intravascular Lithotripsy System

Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.

Shockwave Medical’s IVL System
Shockwave Medica's IVL system • Source: Shockwave Medical

Shockwave Medical has received US Food and Drug Administration approval for its C2 coronary intravascular lithotripsy (IVL) therapy system.

This was described by CEO Doug Godshall as the “most significant achievement” for 2020 in Shockwave’s 2020 year-end sales and...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation